C. Miller, A. Aslo, A. Won, M. Tan, B. Lampkin et al., Alterations of thep53, Rb andMDM2 genes in osteosarcoms, Journal of Cancer Research and Clinical Oncology, vol.70, issue.9, pp.559-565, 1996.
DOI : 10.1007/BF01213553

W. Simonet, D. Lacey, and C. Dunstan, Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-319, 1997.
DOI : 10.1016/S0092-8674(00)80209-3

D. Lacey, E. Timms, and H. Tan, Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, Cell, vol.93, issue.2, pp.165-176, 1998.
DOI : 10.1016/S0092-8674(00)81569-X

S. Theoleyre, Y. Wittrant, S. Tat, Y. Fortun, F. Redini et al., The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-475, 2004.
DOI : 10.1016/j.cytogfr.2004.06.004

S. Tat, M. Padrines, S. Theoleyre, S. Couillaud-battaglia, D. Heymann et al., OPG/membranous???RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation, Bone, vol.39, issue.4, pp.706-715, 2006.
DOI : 10.1016/j.bone.2006.03.016

E. Terpos, R. Szydlo, and J. Apperley, Soluble receptor activator of nuclear factor ??B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index, Blood, vol.102, issue.3, pp.1064-1069, 2003.
DOI : 10.1182/blood-2003-02-0380

E. Grimaud, L. Soubigou, and S. Couillaud, Receptor Activator of Nuclear Factor ??B Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis, The American Journal of Pathology, vol.163, issue.5, pp.2021-2031, 2003.
DOI : 10.1016/S0002-9440(10)63560-2

K. Mori, L. Goff, B. Charrier, C. Battaglia, S. Heymann et al., DU145 human prostate cancer cells express functional receptor activator of NF??B: New insights in the prostate cancer bone metastasis process, Bone, vol.40, issue.4, pp.981-990, 2007.
DOI : 10.1016/j.bone.2006.11.006

D. Jones, T. Nakashima, and O. Sanchez, Regulation of cancer cell migration and bone metastasis by RANKL, Nature, vol.17, issue.7084, pp.692-696, 2006.
DOI : 10.1038/nature04524

Y. Wittrant, F. Lamoureux, K. Mori, A. Riet, A. Kamijo et al., RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells, International Journal of Oncology, vol.28, pp.261-269, 2006.
DOI : 10.3892/ijo.28.1.261

URL : https://hal.archives-ouvertes.fr/inserm-00667510

K. Mori, L. Goff, B. Berreur, and M. , Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, The Journal of Pathology, vol.186, issue.5, pp.555-562, 2007.
DOI : 10.1002/path.2140

L. Meur, N. Lamirault, G. Bihouee, and A. , A dynamic, web-accessible resource to process raw microarray scan data into consolidated gene expression values: importance of replication, Nucleic Acids Research, vol.32, issue.18, pp.5349-5358, 2004.
DOI : 10.1093/nar/gkh870

G. Tseng, M. Oh, L. Rohlin, J. Liao, and W. Wong, Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects, Nucleic Acids Research, vol.29, issue.12, pp.2549-2557, 2001.
DOI : 10.1093/nar/29.12.2549

V. Tusher, R. Tibshirani, and C. G. , Significance analysis of microarrays applied to the ionizing radiation response, Proceedings of the National Academy of Sciences, vol.98, issue.9, pp.5116-5121, 2001.
DOI : 10.1073/pnas.091062498

M. Pfaffl, G. Horgan, and L. Dempfle, Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCR, Nucleic Acids Research, vol.30, issue.9, p.36, 2002.
DOI : 10.1093/nar/30.9.e36

P. Bhatia, M. Sanders, and M. Hansen, Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma, Clin Cancer Res, vol.11, pp.162-165, 2005.

T. Guise, The vicious cycle of bone metastases, J Musculoskelet Neuronal Interact, vol.2, pp.570-572, 2002.

P. Garnero, N. Buchs, J. Zekri, R. Rizzoli, R. Coleman et al., Markers of bone turnover for the management of patients with bone metastases from prostate cancer, British Journal of Cancer, vol.82, issue.4, pp.858-864, 2000.
DOI : 10.1054/bjoc.1999.1012

P. Whang, E. Schwarz, S. Gamradt, W. Dougall, and J. Lieberman, The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone, Journal of Orthopaedic Research, vol.63, issue.6, pp.1475-1483, 2005.
DOI : 10.1016/j.orthres.2005.05.004.1100230634

Y. Lepelletier, I. Moura, and R. Hadj-slimane, Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization, European Journal of Immunology, vol.103, issue.7, pp.1782-1793, 2006.
DOI : 10.1002/eji.200535601

S. Metcalfe, Axotrophin and leukaemia inhibitory factor (LIF) in transplantation tolerance, Philosophical Transactions of the Royal Society B: Biological Sciences, vol.69, issue.6, pp.1687-1694, 2005.
DOI : 10.1002/1097-0290(20000920)69:6<607::AID-BIT4>3.0.CO;2-F

O. Behar, J. Golden, H. Mashimo, F. Schoen, and M. Fishman, Semaphorin III is needed for normal patterning and growth of nerves, bones and heart, Nature, vol.383, issue.6600, pp.525-528, 1996.
DOI : 10.1038/383525a0

C. Gomez, B. Burt-pichat, and F. Mallein-gerin, Expression of Semaphorin-3A and its receptors in endochondral ossification: Potential role in skeletal development and innervation, Developmental Dynamics, vol.4, issue.2, pp.393-403, 2005.
DOI : 10.1002/dvdy.20512

URL : https://hal.archives-ouvertes.fr/ujm-00132076

A. Mani and E. Gelmann, The Ubiquitin-Proteasome Pathway and Its Role in Cancer, Journal of Clinical Oncology, vol.23, issue.21, pp.4776-4789, 2005.
DOI : 10.1200/JCO.2005.05.081

S. Elsasser, R. Gali, and M. Schwickart, Proteasome subunit Rpn1 binds ubiquitin-like protein domains, Nature Cell Biology, vol.4, issue.9, pp.725-730, 2002.
DOI : 10.1038/ncb845

P. Cheung, B. Woolcock, and H. Adomat, Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis, Cancer Research, vol.64, issue.17, pp.5929-5933, 2004.
DOI : 10.1158/0008-5472.CAN-04-1216

E. Schuur, U. Kruse, J. Iacovoni, and P. Vogt, Nuclear factor I interferes with transformation induced by nuclear oncogenes, Cell Growth Differ, vol.6, pp.219-227, 1995.

B. Wong, R. Josien, S. Lee, B. Sauter, H. Li et al., TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell???specific Survival Factor, The Journal of Experimental Medicine, vol.372, issue.12, pp.2075-2080, 1997.
DOI : 10.1084/jem.183.1.7